SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

QuidelOrtho logo
4 days ago

Senior Marketing Manager, Customer Informatics – North America

QuidelOrtho

USA (Remote)Full time$135K/yr – $176K/yr
QuidelOrtho logo
5 months ago

Senior Marketing Manager, Clinical Laboratory Systems

QuidelOrtho

USA (Remote)Full time$135K/yr – $175K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
QuidelOrtho logo

Senior Marketing Manager, Customer Informatics – North America

QuidelOrtho

USA (Remote)

$135K/yr - $176K/yrIn-houseFull-timeSenior level10+ years exp.
4 days ago
QuidelOrtho logo

Senior Marketing Manager, Clinical Laboratory Systems

QuidelOrtho

USA (Remote)

$135K/yr - $175K/yrIn-houseFull-timeSenior level10+ years exp.
5 months ago
QuidelOrtho logo
QuidelOrtho

Senior Marketing Manager, Customer Informatics – North America

USA (Remote)

$135K/yr – $176K/yrSenior Level10+ years expFull time

Posted 4 days ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Description

Responsibilities

  • Lead development and execution of the North America marketing strategy for Informatics solutions aligned to global portfolio strategy and regional commercial priorities
  • Translate global product strategies, positioning, and launch plans into North America-specific market development, segmentation, messaging, and sales enablement plans
  • Evaluate digital health services and solutions that expand the current informatics product portfolio specific to the North American market
  • Present business cases for investment in the digital health services and solutions space
  • Lead launch planning and execution for Informatics and digital health products, features, and upgrades, including field readiness, training, customer targeting, and adoption tracking
  • Develop a clear North America value proposition for Informatics solutions and digital health portfolio, including how they support lab efficiency, workflow optimization, data visibility, clinical decision-making, and customer retention
  • Create high-impact sales tools, messaging, training materials, and customer-facing content to support commercial execution
  • Partner cross-functionally with Sales, Service, Product Management, Marketing, Finance, and Operations to drive commercialization success
  • Monitor Informatics portfolio performance including adoption, utilization, customer feedback, revenue contribution, and competitive positioning
  • Collaborate with sales and service leadership to ensure field teams understand how to position Informatics as part of a broader QuidelOrtho value proposition

Requirements

  • Education: Bachelor’s degree in Marketing, Business, Life Sciences, Healthcare, Informatics, or related field
  • Experience: Typically requires a minimum of 10 years of related experience with a Bachelor’s degree; or 8 years and a Master’s degree; or a PhD with 5 years experience; or equivalent experience
  • Experience commercializing products or solutions in a regulated healthcare or diagnostics environment
  • Strong understanding of healthcare and laboratory customer workflows and market dynamics
  • Demonstrated ability to develop marketing strategies, positioning, launch plans, segmentation, and sales enablement tools
  • Strong communication, presentation, and analytical skills, with ability to translate complex technical capabilities into clear customer value
  • Proven ability to influence cross-functional stakeholders in a matrixed organization
  • Strong business acumen and ability to balance strategic thinking with hands-on execution
  • Travel: Must be willing to travel up to 20% overnight
  • This position is not currently eligible for visa sponsorship

Benefits

  • QuidelOrtho offers a comprehensive benefits package including medical, dental, vision, life, and disability insurance, along with a 401(k) plan, employee assistance program, Employee Stock Purchase Plan, paid time off (including sick time) and paid Holidays. All benefits are non-contractual, and QuidelOrtho may amend, terminate, or enhance the benefits provided, as it deems appropriate.
QuidelOrtho logo

QuidelOrtho

3.0 Glassdoor

> Bringing precision and passion in everything we doQuidelOrtho stands at the forefront of testing, tracking and disease analysis of health conditions ranging from HIV and hepatitis C to flu, strep and COVID-19. For decades, our precision and accuracy have guided clinicians and lab technicians in the moments that matter most. > Continuing our legacy in diagnosticsOur portfolio serves the entire healthcare continuum: from high-volume, high-complexity hospitals and labs to point-of-care, retail and over-the-counter markets. This enables us to continue our legacy of diagnostics in an ever-changing environment where we're passionately pursuing the unknown to advance diagnostic science and care. > Raising the bar in diagnostic careRanked among the world’s largest in vitro diagnostics (IVD) providers, we’re building on more than 120 years of collective experience and innovation. We combine industry-leading expertise in immunoassay and molecular testing with a global footprint in point-of-care settings, clinical labs and transfusion medicine to advance critical diagnostic solutions at scale.> Powering a healthier future for allInspired by a spirit of service, QuidelOrtho is committed to enhancing the wellbeing of people worldwide and happy in the knowledge we are making a difference.To contact us, please visit https://www.quidelortho.com/global/en/contact-us.For career opportunities, please visit: https://careers.quidelortho.com/global/en.#QuidelOrtho #BetterTogether #PowerUpLabs #HealthierFuture #DiagnosticFrontier #AdvancingScience #TalentNetwork

Founded in 1937
3.7K employees (155 in marketing)
QuidelOrtho.com
45% recommend to a friend
39% CEO approval

Salaries

Posted range

$135K/yr – $176K/yr

Taken straight from the job posting.

See all QuidelOrtho salaries

Marketing Team

Marketing Team Size
142 (4% of company)
Median Career Experience
18 years
Median Tenure
3.9 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Maria Fiorino
Maria Fiorino
Senior Director, North America Marketing
At the company for 4 years 8 months

Traffic Signals

Monthly Visitors
75.4K
Traffic Source Mix
Search
48%
Direct
43.1%
Referral
6.6%
Social
1.4%
Paid
0.8%

Headcount Trend

Current headcount: ~3.7K

Recent News

William Blair Has Weak Estimate for QuidelOrtho Q2 Earnings
Oct 11, 2025 • MarketBeat
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
Oct 10, 2025 • The Globe and Mail
QuidelOrtho's (QDEL) Sell (E+) Rating Reaffirmed at Weiss Ratings
Oct 10, 2025 • MarketBeat
QuidelOrtho (QDEL): Exploring Valuation After Analyst Downgrade and Weaker Growth Outlook
Oct 9, 2025 • Yahoo Finance
QuidelOrtho (NASDAQ:QDEL) Shares Gap Down - Here's What Happened
Oct 7, 2025 • MarketBeat
Why QuidelOrtho (QDEL) Stock Is Down Today
Oct 7, 2025 • FinancialContent
Why QuidelOrtho (QDEL) Stock Is Down Today
Oct 7, 2025 • The Globe and Mail
QuidelOrtho's (QDEL) Neutral Rating Reaffirmed at Citigroup
Oct 7, 2025 • MarketBeat
Exploring QuidelOrtho (QDEL) Valuation as Shares Decline 6% to Close at $29.98
Oct 6, 2025 • simplywall.st
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from Brokerages
Oct 2, 2025 • MarketBeat
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
Sep 30, 2025 • Yahoo Finance
QuidelOrtho (QDEL): Valuation Spotlight After New Rapid Flu and COVID Test Launch
Sep 27, 2025 • simplywall.st
QuidelOrtho Releases Episode 51 of Science Bytes Podcast Featuring Dr. Terry O’Neil on Diagnostic Testing in Urgent Care
Sep 25, 2025 • geneonline.com
QuidelOrtho (NASDAQ:QDEL) Trading Down 4.2% - Should You Sell?
Sep 24, 2025 • MarketBeat
Q2 Rundown: QuidelOrtho (NASDAQ:QDEL) Vs Other Medical Devices & Supplies - Imaging, Diagnostics Stocks
Sep 23, 2025 • Yahoo Finance
QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
Sep 22, 2025 • PR Newswire
QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
Sep 22, 2025 • Barchart.com
QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
Sep 22, 2025 • Eastern Progress
QuidelOrtho Introduces QUICKVUE Influenza + SARS Test for Professional Use
Sep 22, 2025 • geneonline.com
10-Minute COVID-19 + Flu Test: QuidelOrtho's New QUICKVUE Device Revolutionizes Point-of-Care Testing
Sep 22, 2025 • Stock Titan
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating
Sep 9, 2025 • Yahoo Finance
Global Diagnostics Leader QuidelOrtho Set for Strategic Discussion at Baird Healthcare Conference 2025
Aug 28, 2025 • Stock Titan
$2.6 Billion Debt Refinancing: QuidelOrtho Secures Major Credit Package with Reduced Payments
Aug 21, 2025 • Stock Titan
QuidelOrtho Completes Debt Refinancing
Aug 21, 2025 • Yahoo Finance
QuidelOrtho completes $3.4 billion debt refinancing to extend maturities
Aug 21, 2025 • Investing.com
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
Aug 19, 2025 • PR Newswire
QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development
Aug 19, 2025 • Finansavisen
QuidelOrtho launches certified analyser programme for rural health facilities
Aug 14, 2025 • Yahoo Finance
QuidelOrtho Launches Certified Analyzer Program
Aug 13, 2025 • PR Newswire
QuidelOrtho launches certified analyzer program for rural healthcare
Aug 13, 2025 • Investing.com
The Top 5 Analyst Questions From QuidelOrtho’s Q2 Earnings Call
Aug 12, 2025 • Yahoo Finance
Earnings Release: Here's Why Analysts Cut Their QuidelOrtho Corporation (NASDAQ:QDEL) Price Target To US$43.14
Aug 9, 2025 • 富途牛牛
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Aug 8, 2025 • Yahoo Finance
QuidelOrtho Topped Estimates But Still Posted A Net Loss
Aug 6, 2025 • Finimize
QuidelOrtho Corp SEC 10-Q Report
Aug 6, 2025 • TradingView
QuidelOrtho Corporation 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:QDEL) 2025-08-06
Aug 6, 2025 • Seeking Alpha
QuidelOrtho's Q2 Financial Performance and Future Outlook - News and Statistics
Aug 6, 2025 • IndexBox
QuidelOrtho Corp (QDEL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...
Aug 6, 2025 • Yahoo Finance
Earnings call transcript: Quidel Ortho’s Q2 2025 EPS beats forecast by 7900%
Aug 5, 2025 • Investing.com
QuidelOrtho’s (NASDAQ:QDEL) Q2 Earnings Results: Revenue In Line With Expectations, Stock Soars
Aug 5, 2025 • TradingView
Quidel stock hits 52-week low at $23.75
Jul 31, 2025 • Investing.com
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ – Company Announcement
Jul 29, 2025 • Financial Times
QuidelOrtho Achieves Triple Crown in Diagnostics: #1 in Service, 17-Point NPS Surge Leads Industry
Jul 29, 2025 • Stock Titan
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™
Jul 29, 2025 • PR Newswire
Why QuidelOrtho (QDEL) Shares Are Sliding Today
Jul 28, 2025 • Yahoo Finance
5 Revealing Analyst Questions From QuidelOrtho’s Q1 Earnings Call
Jul 7, 2025 • Yahoo Finance
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs
Jul 7, 2025 • PR Newswire
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock
Jul 4, 2025 • Nasdaq
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock
Jul 4, 2025 • Yahoo Finance
QuidelOrtho Nabs LEX in $100M M&A
Jun 23, 2025 • San Diego Business Journal
This QuidelOrtho Insider Increased Their Holding In The Last Year
Jun 16, 2025 • simplywall.st
QuidelOrtho seeks FDA approval to complete acquisition of LEX Diagnostics
Jun 6, 2025 • Mugglehead Magazine
QuidelOrtho shifts focus with LEX Diagnostics deal, drops Savanna
Jun 3, 2025 • Investing.com
QuidelOrtho to exit Savanna platform development (QDEL:NASDAQ)
Jun 3, 2025 • Seeking Alpha
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade) (NASDAQ:QDEL)
May 12, 2025 • Seeking Alpha
QuidelOrtho Corp (QDEL) Q1 2025 Earnings Call Highlights: Strong Growth in Core Segments Amid ...
May 8, 2025 • Yahoo Finance
Earnings call transcript: QuidelOrtho Q1 2025 beats EPS, stock up 7.5%
May 7, 2025 • Investing.com
QuidelOrtho to Report First Quarter 2025 Financial Results
Apr 23, 2025 • BioSpace
QuidelOrtho to Report First Quarter 2025 Financial Results | QDEL Stock News
Apr 23, 2025 • GuruFocus
Market Resilience: QuidelOrtho Corporation (QDEL) Finishes Weak at 24.46, Down -0.41
Apr 23, 2025 • DWinneX
QuidelOrtho Co. (NASDAQ:QDEL) Position Reduced by Bank of Montreal Can
Apr 22, 2025 • Defense World
QuidelOrtho (NASDAQ:QDEL) Reaches New 52-Week Low on Analyst Downgrade
Apr 22, 2025 • Defense World
QuidelOrtho Corporation (QDEL) receives a Buy rating from Citigroup
Apr 21, 2025 • knoxdaily.com
QuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by Russell Investments Group Ltd.
Apr 21, 2025 • Defense World
Alliancebernstein L.P. Increases Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)
Apr 19, 2025 • Defense World
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Apr 9, 2025 • Nasdaq
Quidel stock hits 52-week low at $29.67 amid market challenges
Apr 4, 2025 • Investing.com India
Medical Devices & Supplies - Imaging, Diagnostics Stocks Q4 In Review: QuidelOrtho (NASDAQ:QDEL) Vs Peers
Apr 4, 2025 • MSN
Medical Devices & Supplies - Imaging, Diagnostics Stocks Q4 In Review: QuidelOrtho (NASDAQ:QDEL) Vs Peers
Apr 4, 2025 • The Globe and Mail
Raymond James Financial Inc. Makes New $2.17 Million Investment in QuidelOrtho Co. (NASDAQ:QDEL)
Mar 31, 2025 • Defense World
QuidelOrtho Corporation's (NASDAQ:QDEL) Business And Shares Still Trailing The Industry
Mar 30, 2025 • simplywall.st
Supply Chain Management Club Visits QuidelOrtho | Saunders College of Business | RIT
Mar 20, 2025 • Rochester Institute of Technology
QuidelOrtho® Introduces Results Manager™ System
Mar 10, 2025 • BioSpace
QuidelOrtho: Growth Struggles & Negative GAAP Earnings (NASDAQ:QDEL)
Feb 20, 2025 • Seeking Alpha
$30+ Bn Primary Care POC Diagnostics Market Opportunities and Strategies to 2033: F. Hoffmann-La Roche Leads with 10.51% Share, Followed by Siemens Healthineers and QuidelOrtho
Feb 19, 2025 • GlobeNewswire
Why QuidelOrtho Stock Bounced More Than 4% Higher Today
Feb 13, 2025 • The Motley Fool
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
Feb 12, 2025 • BioSpace
QuidelOrtho’s (NASDAQ:QDEL) Q4: Beats On Revenue But Full-Year Sales Guidance Misses Expectations
Feb 12, 2025 • Yahoo Finance
Los Angeles Rams and Quidel Ortho Team Up for a Winning STEAM Event
Jan 30, 2025 • Los Angeles Sentinel
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
Jan 13, 2025 • BioSpace
QuidelOrtho Announces Appointment of Two Independent Directors to its Board
Dec 10, 2024 • Business Wire
Watkins Advises Carlyle on Secondary Offering of QuidelOrtho Corporation Common Stock
Nov 22, 2024 • Latham & Watkins LLP
Carlyle group sells $291.7 million in QuidelOrtho shares
Nov 21, 2024 • Investing.com
QuidelOrtho announces executive leadership changes
Nov 8, 2024 • Investing.com

Links

QuidelOrtho.comLinkedInX (Twitter)